Harmony Biosciences Holdings, Inc. reported second-quarter 2026 financial results on August 4, 2026. Net product revenue for WAKIX reached $261.3 million, a 30% increase year-over-year, driven by an estimated average patient count of 8,950. The company reaffirmed its full-year net revenue guidance of $1.0 billion to $1.04 billion. Net income was $75.4 million, or $1.28 per diluted share, compared to $39.8 million in the prior year period. Operating expenses decreased 5% to $108.8 million due to lower R&D and G&A costs relative to prior-year charges. The company also announced encouraging Phase 1 single ascending dose data for its orexin-2 agonist BP-205, highlighting favorable pharmacokinetic profiles and safety. Harmony maintains a strong liquidity position of $962.5 million in cash, cash equivalents, and investments as of June 30, 2026. The company operates in the pharmaceutical industry, developing and commercializing therapies for rare neurological diseases.

On July 16, 2026, Harmony Biosciences reported preliminary Q2 2026 net product revenue for WAKIX of approximately $261 million, a 30% increase year-over-year and a record quarterly result. The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion. Simultaneously, the company announced that CFO Glenn Reicin stepped down effective July 16, 2026, to pursue other opportunities. Stephen Mollichella, Senior Vice President and Controller, was appointed as Interim Principal Financial Officer. Full Q2 2026 financial results are scheduled for release on August 4, 2026. The company is a pharmaceutical company that develops and commercializes therapies for rare neurological diseases.